Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age

NCT02890381 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
17
Enrollment
NIH
Sponsor class

Stopped Interim data indicated this vaccine will not meet the protocol criteria for a good vaccine candidate.

Conditions

Interventions

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)